Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
KARD · NASDAQ · Pharmaceutical Preparations · No 10-K yet
Kardigan (KARD) · oqro.io/stocks/KARD · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$13.82−0.30 (−2.12%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
No open-market purchase by an insider of Kardigan is on record in SEC filings since 2006.
No open-market sale by an insider of Kardigan (KARD) was filed with the SEC in the last 90 days.
No trade in Kardigan (KARD) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−37.2% (−$8.18) from Jun 18, 2026 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $22.00 on Jun 18, 2026 to $13.82 on Nov 13, 2026 (−37.2%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 4 13F position changes for 2 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in South San Francisco, CA. Listed, but no annual report (10-K) filed yet under this SEC registration.
Last 12 months
Not enough history
Market value
$1.29B
Short interest: 5.69M shares sold short (6.1% of shares outstanding), +7.4% vs the previous count, 11.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $384M, at Jun 30, 2026
Net income, last 12 months
—
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Fund moves
From a 13F filed Nov 13, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
10 tracked managers disclosed the same change for Q2 2026. Among this manager's largest new positions for Q2 2026.
Fund moves
10 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
2 certified in FY2026 Q3, vs 1 a year earlier. 2 positions in total, median offered wage $167K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
3 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in hypertension, symptomatic genetic dilated cardiomyopathy, moderate aortic valve stenosis. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Against the S&P 500 over the year
Since Jun 18, 2026, KARD is down 37.2% and the index fund is up 1.0%: 38 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much KARD moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Fails to deliver: 90K shares (about $1.49M) were not delivered on time for settlement on Sep 21, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
On the public record for Kardigan over the 12 months to Nov 14, 2026: 4 clinical trials.
